CXCR3, CCR5, and CRTH2 Chemokine Receptor Expression in Lymphocytes Infiltrating Thyroid Nodules with Coincident Hashimoto’s Thyroiditis Obtained by Fine Needle Aspiration Biopsy

Table 2

Chemokine expression in thyroid-infiltrating lymphocytes from nodules obtained by FNAB and from peripheral blood.

	FNAB samples^1		Peripheral blood
	Patients (thyroid nodules with Hashimoto’s thyroiditis)	Controls (pure thyroid nodules)	Patients (thyroid nodules with Hashimoto’s thyroiditis)	Controls (pure thyroid nodules)
	42	58	46	60
CXCR3 (%)	62.7 (33.16–84.23)	55.00 (23.51–74.86)	40.0 (30.34–43.55)	35.5 (27.88–41.74)	n.s.
					n.s.
					CCR5 (%)	30.5 (18.8–40.5)	34.75 (14.35–54.78)	16.83 (13.00–24.50)	17.5 (12.94–27.28)	n.s.
										n.s.
CXCR3 and CCR5 (%)	26.6 (10.35–37.0)	21.75 (8.8–53.3)	9.5 (6.45–16.23)	10.3 (6.93–15.5)						n.s.
										n.s.
					CRTH2 (%)	13.95 (5.35–38.05)	6.7 (3.73–14.51)	6.7 (4.13–12.15)	5.13 (2.7–6.75)
										n.s.
CXCR3 and CRTH2 (%)	11.7 (2.05–23.1)	7.15 (3.3–15.6)	1.8 (0.95–3.25)	1.7 (1.1–3.95)						n.s.
										n.s.
					CCR5 and CRTH2 (%)	1.8 (0.175–20.6)	3.1 (0.5–7.6)	0.4 (0.2–1.08)	0.35 (0.2–1.0)	n.s.
										n.s.
n.s.

Expressed as median percentage of lymphocytes with expression of individual chemokines, median (lower quartile-upper quartile). : number of patients/nodules, FNAB: fine needle aspiration biopsy, : FNAB/patients versus FNAB/controls, : peripheral blood/patients versus peripheral blood/controls, : FNAB/patients versus peripheral blood/patients, and : FNAB/controls versus peripheral blood/controls.
¹85 were benign hyperplastic nodules (Bethesda II category), 8 were neoplastic nodules (Bethesda categories IV, V, or VI), 4 were atypias of undetermined significance/follicular lesions of undetermined significance (Bethesda III category), and 3 were nondiagnostic (Bethesda I category).